Table 1 Association of BRCA1 and BRCA2 mRNA-expression and mutations with clinicopathological characteristics in 201 ovarian cancer patients
From: BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer
Variable | Number (%) | mRNA expression values (arbitrary units) | Somatic mutations | DNA methylation status | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRCA1 | BRCA2 | BRCA1 | BRCA2 | BRCA1 | ||||||||||
Median (IQR) | P value | Median (IQR) | P value | Non-mutated (%) | Mutated (%) | P value | Non-mutated (%) | Mutated (%) | P value | Unmethylated (%) | Methylated (%) | P value | ||
Age | ||||||||||||||
≤62.3 years | 101 (50%) | 0.81 (0.53–1.30) | 0.491 | 3.72 (2.14–6.15) | 0.875 | 73 (73%) | 27 (27%) | 0.001 | 95 (94%) | 5 (5%) | 0.743 | 88 (88%) | 12 (12%) | 0.504 |
>62.3 years | 100 (50%) | 0.86 (0.55–1.37) | 3.65 (2.47–6.01) | 90 (90%) | 9 (9%) | 93 (93%) | 6 (6%) | 90 (91%) | 9 (9%) | |||||
FIGO stage | ||||||||||||||
I/II | 50 (25%) | 0.91 (0.57–1.35) | 0.361 | 3.22 (2.08–4.87) | 0.089 | 42 (84%) | 7 (14%) | 0.426 | 48 (96%) | 1 (2%) | 0.219 | 48 (96%) | 2 (4%) | 0.081 |
III/IV | 151 (75%) | 0.80 (0.53–1.30) | 4.02 (2.67–6.17) | 121 (80%) | 29 (19%) | 140 (93%) | 10 (7%) | 130 (87%) | 19 (13%) | |||||
Tumor grade | ||||||||||||||
1 | 14 (7%) | 0.52 (0.43–1.01) | 0.099 | 2.07 (1.19–2.92) | <0.001 | 12 (86%) | 2 (14%) | 0.789 | 14 (100%) | 0 (0%) | 0.624 | 13 (93%) | 1 (7%) | 0.004 |
2 | 90 (45%) | 0.85 (0.56–1.26) | 3.55 (2.22–5.35) | 71 (80%) | 18 (20%) | 84 (94%) | 5 (6%) | 87 (97%) | 3 (3%) | |||||
3 | 95 (47%) | 0.82 (0.58–1.55) | 4.51 (3.00–7.30) | 78 (83%) | 16 (17%) | 88 (94%) | 6 (6%) | 76 (82%) | 17 (18%) | |||||
n.a. | 2 (1%) | – | – | – | – | – | ||||||||
Residual disease | ||||||||||||||
Macroscopically tumor-free | 100 (50%) | 0.87 (0.58–1.34) | 0.261 | 3.36 (2.04–5.16) | 0.032 | 82 (82%) | 17 (17%) | 0.588 | 92 (92%) | 7 (7%) | 0.399 | 94 (95%) | 5 (5%) | 0.013 |
Any tumor residual | 95 (47%) | 0.78 (0.51–1.33) | 3.99 (2.82–6.23) | 75 (79%) | 19 (20%) | 90 (95%) | 4 (4%) | 79 (84%) | 15 (16%) | |||||
n.a. | 6 (3%) | |||||||||||||
Histology | ||||||||||||||
HGSOC | 129 (64%) | 0.79 (0.55–1.31) | 0.025 | 4.13 (2.59–6.16) | 0.005 | 102 (79%) | 25 (19%) | 0.848 | 117 (91%) | 10 (8%) | 0.314 | 114 (89%) | 14 (11%) | 0.993 |
LGSOC | 12 (6%) | 0.48 (0.38–0.67) | 2.05 (1.16–2.87) | 10 (83%) | 2 (17%) | 12 (100%) | 0 (0%) | 11 (92%) | 1 (8%) | |||||
Endometrioid | 45 (22%) | 1.05 (0.68–1.48) | 4.44 (2.91–6.40) | 37 (82%) | 8 (18%) | 44 (98%) | 1 (2%) | 40 (89%) | 5 (11%) | |||||
Clear cell | 11 (5%) | 0.97 (0.74– 1.44) | 2.88 (2.00–4.56) | 10 (91%) | 1 (9%) | 11 (100%) | 0 (0%) | 9 (90%) | 1 (10%) | |||||
Unknown | 4 (2%) | – | – | – | – | – | – | – | – | |||||
Ovarian cancer type | ||||||||||||||
Type I | 14 (7%) | 0.52 (0.43–1.00) | 0.034 | 2.07 (1.19–2.92) | 0.001 | 12 (86%) | 2 (14%) | 0.676 | 14 (100%) | 0 (0%) | 0.342 | 13 (93%) | 1 (7%) | 0.650 |
Type II | 183 (91%) | 0.85 (0.57–1.36) | 4.09 (2.63–6.16) | 147 (80%) | 34 (19%) | 170 (93%) | 11 (6%) | 161 (89%) | 20 (11%) | |||||
Unknown | 4 (2%) | – | – | – | – | – | – | |||||||
BRCA1 mutation | ||||||||||||||
Wild type | 163 (81%) | 0.90 (0.57–1.40) | 0.014 | 3.48 (2.23–5.48) | 0.001 | – | – | – | – | – | – | 141 (87%) | 21 (13%) | 0.024 |
Mutate | 36 (18%) | 0.66 (0.42–0.89) | 5.92 (3.27–8.38) | – | – | – | – | 35 (100%) | 0 (0%) | |||||
n.a. | 2 (1%) | – | – | |||||||||||
BRCA2 mutation | ||||||||||||||
Wild type | 188 (94%) | 0.82 (0.53–1.29) | 0.073 | 3.84 (2.46–6.16) | 0.346 | – | – | – | – | – | – | 166 (89%) | 20 (11%) | 0.862 |
Mutate | 11 (6%) | 1.59 (0.59–2.39) | 3.40 (1.97–4.18) | – | – | – | – | 10 (91%) | 1 (9%) | |||||
n.a. | 2 (1%) | – | – | |||||||||||
BRCA1/2 mutation | ||||||||||||||
Wild type | 152 (76%) | 0.88 (0.55–1.33) | 0.178 | 3.48 (2.26–5.51) | 0.015 | – | – | – | – | – | – | 131 (87%) | 20 (13%) | 0.033 |
Mutate | 47 (24%) | 0.68 (0.44–1.35) | 5.14 (2.80–7.55) | 45 (98%) | 1 (2%) | |||||||||
n.a. | 2 (1%) | – | – | – | – | – | – | |||||||
BRCA1 DNA methylation | ||||||||||||||
Unmethylated | 178 (89%) | 0.88 (0.58–1.35) | <0.001 | 3.41 (2.17–5.78) | 0.001 | – | – | – | – | – | – | – | – | – |
Methylated | 21 (11%) | 0.20 (0.14–0.46) | 5.52 (3.99–8.21) | – | – | – | – | – | – | |||||
BRCA2 DNA methylation | ||||||||||||||
Unmethylated | 168 (100%) | 0.78 (0.53–1.28) | – | 3.68 (2.36–6.01) | – | – | – | – | – | – | – | |||
Methylated | 0 (0%) | – | – | – | – | – | – | – | ||||||
